Ahmad 
The Russian Ministry of Health announced the registration of the world’s first treatment for “Pichterev” disease, a type of rheumatoid spondylarthritis.
This disease is a chronic condition that mainly affects the spine and sacroiliac joint, where the immune system misrecognizes cartilage and joint tissue and treats them as foreign bodies, leading to pain and stiffness and limiting movement.
According to Russian health reports, the new drug was developed in cooperation between the Russian National Research Medical University “Pirogov” and the “Shemyakin and Ovchennikov” Institute of Biochemistry, in addition to the Russian pharmaceutical company “BIOCAD”.
The drug has shown high efficacy and safety during clinical trials, and the World Health Organization has given the drug the international name “seniprutug”, according to which it will be circulated with an information leaflet on the treatment in the medical and pharmaceutical community globally.
The new drug destroys pathological T lymphocytes that attack the body, and Sergey Lukyanov, president of the Russian National Medical Research University and one of the drug’s developers, stressed that “the new treatment completely stops the disease without suppressing the immune system or causing addiction.”
The manufacturer, after registering the drug, will begin industrial production of the treatment, paving the way for its provision to patients with this chronic condition.
Libya’s notable participation in the Victory Day celebration in Moscow